Coagulation markers and outcomes in acute coronary syndromes

American Heart Journal

Volumn 136, Issue 4 II SUPPL., 1998, Pages

  Ardissino, D ^a   Merlini, P A ^a   Eisenberg, P R ^a   Kottke Marchant, K ^a   Crenshaw, B S ^a   Granger, C B ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 7; FIBRINOPEPTIDE A; PROTHROMBIN; THROMBIN;

BLOOD CLOTTING; CORONARY ARTERY THROMBOSIS; DIAGNOSTIC VALUE; FIBRINOLYTIC THERAPY; HEART INFARCTION; HUMAN; PRIORITY JOURNAL; REVIEW; UNSTABLE ANGINA PECTORIS;

EID: 0031735546     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1053/hj.1998.v136.93436     Document Type: Article

References (55)

1. V Fuster L Badimon JJ Badimon JH. Chesebro The pathogenesis of coronary artery disease and the acute coronary syndromes: part 1 N Engl J Med 326 1992 242 250
2. V Fuster L Badimon JJ Badimon JH. Chesebro The pathogenesis of coronary artery disease and the acute coronary syndromes: part 2 N Engl J Med 326 1992 310 318
3. KA Bauer RD. Rosenberg The pathophysiology of the prethrombotic state in humans: insight gained from studies using markers of hemostatic system activation Blood 70 1987 343 350
4. TW Meade S Mellows M Brozovic GJ Miller RR Chakrabarti WRS. North Haemostatic function and ischemic heart disease: principal results of the Norwick Park Heart Study Lancet 2 1986 533 537
5. J Heinrich L Balleisen H Schulte G Assmann J. van de Loo Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men Arterioscler Thromb 14 1994 54 59
6. SG Thompson J Kienast SDM Pyke F Haverkate JCW van de Loo for the European Concerted Action on Thrombosis Disabilities Angina Pectoris Study Group N Engl J Med 332 1995 635 641
7. TW Meade J Cooper GJ Miller D Howarth Y. Stirling Antithrombin III and arterial disease: an unexpected relationship Lancet 337 1991 850 851
8. TW Meade V Ruddock Y Stirling R Chakrabarti GJ. Miller Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study Lancet 342 1993 1076 1079
9. A Hamsten U deFaire G Wallius Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction Lancet 2 1987 3 9
10. TW Meade Y Stirling TP Welch MR. Crompton Fibrinopeptide A and sudden coronary death Lancet 2 1984 607 609
11. GJ Miller KA Bauer S Barzegar JA Cooper RD. Rosenberg Increased activation of the hemostatic system in men at high risk of fatal coronary artery disease Thromb Haemost 75 1996 767 771
12. D Ardissino PA Merlini G Gamba Thrombin activity and early outcome in unstable angina pectoris Circulation 93 1996 1634 1639
13. CB Granger R Becker RP Tracy for the GUSTO Hemostasis Substudy Group Thrombin generation, inhibition, and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: results from the GUSTO trial J Am Coll Cardiol 31 1998 497 505
14. PA Merlini KA Bauer L Oltrona Persistent activation of the coagulation mechanism in unstable angina and myocardial infarction Circulation 90 1994 61 68
15. P Theroux H Ouimet J McCains Aspirin, heparin or both to treat acute unstable angina N Engl J Med 319 1988 1105 1111
16. Randomised controlled trial of subcutaneous calcium-heparin in acute myocardial infarction. The SCATI (Studio sulla Calciparina nell’Angina e nella Trombosi Ventricolare nell’Infarto Miocardico) Lancet 2 1989 182 186
17. G Mombelli I Hof A Haeberli PW. Straub Effect of heparin on plasma fibrinopeptide A in patients with acute myocardial infarction Circulation 69 1984 684 689
18. A Gallino A Haeberli T Hess G Mombelli PW. Straub Fibrin formation and platelet aggregation in patients with acute myocardial infarction: effect of intravenous and subcutaneous low-dose heparin Am Heart J 112 1986 285 290
19. PA Merlini D Ardissino KA Bauer Persistent thrombin generation during heparin therapy in patients with acute coronary syndromes Arterioscler Thromb Vasc Biol 17 1997 1325 1330
20. AK Rao L Sun JH Chesebro for the Hirudin in Unstable Angina Trial Distinct effects of recombinant desulfstohirudin (Revasc) and heparin on plasma levels of fibrinopeptide A and prothrombin fragment 1+2 in unstable angina Circulation 94 1996 2389 2395
21. JD Marmur PA Merlini SK Sharma Thrombin generation in human coronary arteries after percutaneous transluminal balloon angioplasty J Am Coll Cardiol 24 1994 1484 1491
22. L Oltrona PR Eisenberg JM Lasala DJ Sewall ME Shelton KJ. Winters Association of heparin-resistant thrombin activity with acute ischemic complications of coronary interventions Circulation 94 1996 2064 2071
23. PR Eisenberg LA Sherman AS. Jaffe Paradoxic elevation of fibrinopeptide A after streptokinase: evidence of continued thrombosis despite intense fibrinolysis J Am Coll Cardiol 10 1987 527 529
24. PR Eisenberg BE Sobel AS. Jaffe Activation of prothrombin accompanying thrombolysis with recombinant tissue-type plasminogen activator J Am Coll Cardiol 19 1992 1065 1069
25. HJ Rapold D deBono AER Arnold Plasma fibrinopeptide A levels in patients with myocardial infarction treated with alteplase Circulation 85 1992 928 934
26. PA Merlini K Bauer L Oltrona Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction J Am Coll Cardiol 25 1995 203 209
27. DC Gulba M Barthels M Westhoff-Bleck Increased thrombin levels during thrombolytic therapy in acute myocardial infarction Circulation 83 1991 937 944
28. PA Merlini D Ardissino K Bauer Activation of the hemostatic mechanism during thrombolysis in patients with unstable angina pectoris Blood 86 1995 3327 3332
29. AJ Tiefenbrunn RA Graor AK Robison FV Lucas A Hotchkiss BE. Sobel Pharmacodynamics of tissue-type plasminogen activator characterized by computer assisted simulation Circulation 73 1986 1291 1299
30. HL Nossel RE Yudelman VP Canfield Measurement of fibrinopeptide A in human blood J Clin Invest 54 1974 43 53
31. B Blomback M Blomback P Edman B. Hessel Human fibrinopeptides: isolation, characterization and structure Biochim Biophys Acta 115 1966 371 396
32. HL Nossel VPJ Butler GD Wilner RE Canfield EJ. Harfenist Specificity of antisera to human fibrinopeptide A used in clinical fibrinopeptide A assays Thromb Haemost 35 1976 101 109
33. C Kochum S. Frebelius Rapid radioimmunoasay of human fibrinopeptide A-removal of cross-reacting fibrinogen with bentonite Thromb Res 19 1980 589 598
34. L Bajzar R Manuel ME. Nesheim Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor J Biol Chem 270 1995 14477 14484
35. JI Weitz MK Cruickshank B Thong Human tissue-type plasminogen activator releases fibrinopeptides A and B from fibrinogen J Clin Invest 82 1988 1700 1707
36. G Mombelli V Im Hof A Haeberli PW. Straub Effect of heparin on plasma fibrinopeptide A in patients with acute myocardial infarction Circulation 69 1984 684 689
37. DA Mehs KR Siebenlist G Bergstrom MW. Mosesson Sequences of release of fibrinopeptide A from fibrinogen molecules by thrombin or Atraxin J Lab Clin Med 125 1995 384 391
38. LV Lee GA Ewald CR McKenzie PR. Eisenberg The relationship of soluble fibrin and cross-linked fibrin degradation products to the clinical course of myocardial infarction Arterioscler Thromb Vasc Biol 17 1997 628 633
39. W Nieuwenhuizen EH Nobel R. Laterveer A rapid immunoassay (EIA) for the quantitative determination of soluble fibrin in plasma Thromb Haemost 68 1992 273 277
40. RD Rosenberg PS. Damus The purification and mechanism of action of human antithrombin-heparin cofactor J Biol Chem 248 1973 6490 6505
41. H Pelzer A Schwarz N. Heimburger Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay Thromb Haemost 59 1988 101 106
42. JS Scharfstein DR Abendschein PR Eisenberg Usefulness of fibrinogenolytic and procoagulant markers during thrombolytic therapy in predicting clinical outcomes in acute myocardial infarction Am J Cardiol 78 1996 503 510
43. DC Gulba M Barthels M Westhoff-Bleck Increased thrombin levels during thrombolytic therapy in acute myocardial infarction. Relevance for the success of therapy Circulation 83 1991 937 944
44. 1+2 fragment and thrombin-antithrombin complex Blood 59 1982 1086 1097
45. 1+2 values measured by two commercial ELISA methods: influence of different anticoagulants and standards Thromb Haemost 71 1994 605 608
46. PA Merlini KA Bauer L Oltrona Persistent activation of coagulation mechanism in unstable angina and myocardial infarction Circulation 90 1994 61 68
47. P Zoldhelyi J Bichler WG Owen Persistent thrombin generation in humans during specific thrombin inhibition with hirudin Circulation 90 1994 2671 2678
48. PR Eisenberg BE Sobel AS. Jaffe Activation of prothrombin accompanying thrombolysis with rt-PA J Am Coll Cardiol 19 1992 1065 1069
49. PJ Gaffney M. Brasher Subunit structure of the plasmin degradation products of crosslinked fibrin Biochem Biophys Acta 295 1973 308 313
50. CW Francis VJ Marder GA. Barlow Plasmic degradation of crosslinked fibrin, characterization of new macromolecular soluble complexes, and a model of their structure J Clin Invest 66 1980 1033 1043
51. PJ Gaffney LJ Creighton MJ Perry M Callus R Thorpe M. Spitz Monoclonal antibodies to crosslinked fibrin degradation products (XL-FDP). I. Characterization and preliminary evaluation in plasma Br J Haematol 68 1988 83 90
52. PR Eisenberg AS Jaffe DC Stump D Collen EG. Bovill Validity of enzyme-linked immunosorbent assays of cross-linked fibrin degradation products as a measure of clot lysis Circulation 82 1990 1159 1168
53. MA John MJ Elms EJ O’Reilly DB Rylatt PG Bundesen CJ Hillyard The SimpliRed D-dimer test: a novel assay for the detection of cross-linked fibrin degradation products in whole blood Thrombs Res 58 1990 273 281
54. H Bounameaux P de Moerloose A Perrier G. Reber Plasma measurement of D-dimer as diagnostic aid in suspected venous thromboembolism: an overview Thromb Haemosts 71 1994 1 6
55. PR Eisenberg DB Rylatt F Rusticali D Ferrini F Ottani M. Galvani Importance of assay specificity in interpretation of cross-linked fibrin degradation in patients treated with fibrinolytic agents Blood Coag Fibrinol 8 1997 105 113